7- amino- 2- (((2- methyl- 1- (3- phenylpropanoylamino)propyl)hydroxyphosphinoyl)methyl)heptanoic acid

inhibits plasma carboxypeptidase B; structure in first source

Also Known As:

EF 6265; EF-6265; EF6265

Networked: 3 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Amino Acids: 30675
  - 7-amino-2-(((2-methyl-1-(3-phenylpropanoylamino)propyl)hydroxyphosphinoyl)methyl)heptanoic acid: 3
Inorganic Chemicals: 9
- Acids: 53217
  - Noncarboxylic Acids
    - Phosphorus Acids: 1
      - Phosphinic Acids: 18
        7-amino-2-(((2-methyl-1-(3-phenylpropanoylamino)propyl)hydroxyphosphinoyl)methyl)heptanoic acid: 3
- Phosphorus Compounds: 84
  - Phosphorus Acids: 1
    - Phosphinic Acids: 18
      - 7-amino-2-(((2-methyl-1-(3-phenylpropanoylamino)propyl)hydroxyphosphinoyl)methyl)heptanoic acid: 3
Organic Chemicals: 133
- Organophosphorus Compounds: 300
  - Phosphinic Acids: 18
    - 7-amino-2-(((2-methyl-1-(3-phenylpropanoylamino)propyl)hydroxyphosphinoyl)methyl)heptanoic acid: 3

Experts

1.	Iida, Hiroyuki: 3 articles (05/2009 - 05/2004)
2.	Ishii, Hidemi: 3 articles (05/2009 - 05/2004)
3.	Muto, Yuko: 3 articles (05/2009 - 05/2004)
4.	Suzuki, Kokichi: 3 articles (05/2009 - 05/2004)
5.	Kato, Emiko: 2 articles (05/2009 - 05/2004)
6.	Itoh, Fumi: 1 article (05/2009)
7.	Kakui, Nobukazu: 1 article (05/2009)
8.	Sakakibara, Shiro: 1 article (05/2009)
9.	Fushihara, Kenichi: 1 article (05/2004)
10.	Kanemoto, Ken-ichi: 1 article (05/2004)

Related Diseases

1.	Edema (Dropsy) 01/01/2007 - "The elevation of blood urea nitrogen and renal edema formation decreased, and the reduction of the urine volume improved after a long-term treatment (21 h) with EF6265. "
2.	Sepsis (Septicemia) 05/01/2009 - "We performed the pharmacologic study to assess the effect of EF6265, a specific inhibitor of activated form of TAFI (TAFIa) on sepsis-induced organ dysfunction models. " 05/01/2009 - "EF6265, a novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor, protects against sepsis-induced organ dysfunction in rats." 05/01/2009 - "In the sepsis model, EF6265, simultaneously administered with ceftazidime (CAZ) 2 hours after Pseudomonas aeruginosa injection, showed no influence on the antibiotic activity of CAZ. "
3.	Glomerulonephritis 01/01/2007 - "In the present study, the effects of EF6265, a novel specific plasma carboxypeptidase B inhibitor, on renal dysfunction in a rat thrombotic glomerulonephritis model were examined. " 01/01/2007 - "EF6265, which inhibits plasma carboxypeptidase B, showed a protective effect on thrombotic renal dysfunction in thrombotic glomerulonephritis through enhancing the fibrinolysis." 01/01/2007 - "EF6265, a novel plasma carboxypeptidase B inhibitor, protects against renal dysfunction in rat thrombotic glomerulonephritis through enhancing fibrinolysis."
4.	Endotoxemia 05/01/2009 - "In the endotoxemia model, posttreatment (1 hour) with EF6265 reduced fibrin deposits in the kidney and liver accompanied by no significant changes in platelet count and fibrinogen concentration in plasma. "
5.	Thrombosis (Thrombus) 05/01/2004 - "To target thrombosis in a new way, we have identified and optimized a phosphinic acid-containing inhibitor of CPB, EF6265 [(S)-7-amino-2-[[[(R)-2-methyl-1-(3-phenylpropanoylamino) propyl]hydroxyphosphinoyl]methyl]heptanoic acid] and determined both the pharmacological profile and pathophysiological role of CPB in rat thrombolysis. "

Related Drugs and Biologics

1.	Urea (Carbamide)
2.	Nitrogen
3.	Carboxypeptidase B
4.	Carboxypeptidase B2 (Thrombin Activatable Fibrinolysis Inhibitor)
5.	Phosphinic Acids (Phosphinic Acid)
6.	Fibrinogen (Factor I)
7.	Fibrin
8.	Ceftazidime (Fortum)
9.	Anti-Bacterial Agents (Antibiotics)
10.	Acids